Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic breast cancer after 2 or more types of chemotherapy
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a
Evidence-based recommendations on dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant/intolerant chronic myeloid leukaemia in adults
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and imatinib (Glivec) for untreated chronic myeloid leukaemia in adults
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events such as heart attacks or stroke after myocardial infarction (MI)
Evidence-based recommendations on the XprESS multi-sinus dilation system for treating chronic sinusitis after medical treatment has failed
Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults
Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults
Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults
Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C (HCV) in adults
Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for unresectable or metastatic melanoma in adults with a BRAF V600
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor
Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases
Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing
Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults
Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (NSCLC) in adults
Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults
Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had
Evidence-based recommendations on ramucirumab (Cyramza) for treating previously treated locally advanced or metastatic non-small-cell lung cancer
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults
Evidence-based recommendations on cabazitaxel (Jevtana) for prostate cancer that has come back after it was treated with docetaxel
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults
Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del
Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia (AML) with more than 30% bone marrow blasts
Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults
Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600
Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia
Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia
Evidence-based recommendations on belimumab (Benlysta) as an add-on treatment for active autoantibody-positive systemic lupus erythematosus
Evidence-based recommendations on ceritinib (Zykadia) for advanced anaplastic lymphoma kinase positive non-small-cell lung cancer...
Evidence-based recommendations on GreenLight XPS for treating benign prostatic hyperplasia
Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) for treating type 2 diabetes in adults
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction
Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine
Evidence-based recommendations on ruxolitinib (Jakavi) for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.
Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in people with sickle cell disease
Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.
Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet
Evidence-based recommendations on ramucirumab (Cyramza)
Evidence-based recommendations on nintedanib (Ofev) for people with idiopathic pulmonary fibrosis.